Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Mereo BioPharma (MREO) Non Operating Investment Income (2023 - 2025)

Mereo BioPharma (MREO) has disclosed Non Operating Investment Income for 3 consecutive years, with $294000.0 as the latest value for Q4 2025.

  • Quarterly Non Operating Investment Income rose 87.26% to $294000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $805000.0 through Dec 2025, up 292.12% year-over-year, with the annual reading at $805000.0 for FY2025, 292.12% up from the prior year.
  • Non Operating Investment Income for Q4 2025 was $294000.0 at Mereo BioPharma, up from $196000.0 in the prior quarter.
  • The five-year high for Non Operating Investment Income was $542000.0 in Q1 2023, with the low at -$448000.0 in Q1 2024.
  • Average Non Operating Investment Income over 3 years is $57363.6, with a median of -$59000.0 recorded in 2024.
  • The sharpest move saw Non Operating Investment Income tumbled 182.66% in 2024, then soared 432.2% in 2025.
  • Over 3 years, Non Operating Investment Income stood at -$195000.0 in 2023, then soared by 180.51% to $157000.0 in 2024, then skyrocketed by 87.26% to $294000.0 in 2025.
  • According to Business Quant data, Non Operating Investment Income over the past three periods came in at $294000.0, $196000.0, and -$101000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.